Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.27
XRAY's Cash to Debt is ranked lower than
83% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. XRAY: 0.27 )
Ranked among companies with meaningful Cash to Debt only.
XRAY' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.08 Max: 1.01
Current: 0.27
0.02
1.01
Equity to Asset 0.72
XRAY's Equity to Asset is ranked higher than
66% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. XRAY: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
XRAY' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.52 Max: 0.72
Current: 0.72
0.34
0.72
Interest Coverage 6.43
XRAY's Interest Coverage is ranked lower than
74% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.08 vs. XRAY: 6.43 )
Ranked among companies with meaningful Interest Coverage only.
XRAY' s Interest Coverage Range Over the Past 10 Years
Min: 6.71  Med: 10.60 Max: 29.14
Current: 6.43
6.71
29.14
F-Score: 8
Z-Score: 3.55
M-Score: -1.72
WACC vs ROIC
10.67%
7.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.55
XRAY's Operating margin (%) is ranked higher than
71% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. XRAY: 12.55 )
Ranked among companies with meaningful Operating margin (%) only.
XRAY' s Operating margin (%) Range Over the Past 10 Years
Min: 11.85  Med: 16.19 Max: 17.66
Current: 12.55
11.85
17.66
Net-margin (%) 11.19
XRAY's Net-margin (%) is ranked higher than
79% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. XRAY: 11.19 )
Ranked among companies with meaningful Net-margin (%) only.
XRAY' s Net-margin (%) Range Over the Past 10 Years
Min: 9.39  Med: 11.51 Max: 12.94
Current: 11.19
9.39
12.94
ROE (%) 8.93
XRAY's ROE (%) is ranked higher than
62% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. XRAY: 8.93 )
Ranked among companies with meaningful ROE (%) only.
XRAY' s ROE (%) Range Over the Past 10 Years
Min: 10.78  Med: 14.98 Max: 18.61
Current: 8.93
10.78
18.61
ROA (%) 5.32
XRAY's ROA (%) is ranked higher than
64% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.92 vs. XRAY: 5.32 )
Ranked among companies with meaningful ROA (%) only.
XRAY' s ROA (%) Range Over the Past 10 Years
Min: 5.55  Med: 7.51 Max: 10.69
Current: 5.32
5.55
10.69
ROC (Joel Greenblatt) (%) 30.36
XRAY's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.41 vs. XRAY: 30.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XRAY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 31.15  Med: 42.07 Max: 54.55
Current: 30.36
31.15
54.55
Revenue Growth (3Y)(%) -2.70
XRAY's Revenue Growth (3Y)(%) is ranked lower than
72% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. XRAY: -2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XRAY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.7  Med: 8.50 Max: 21.8
Current: -2.7
-2.7
21.8
EBITDA Growth (3Y)(%) -0.20
XRAY's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. XRAY: -0.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XRAY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.4  Med: 8.40 Max: 50.5
Current: -0.2
-22.4
50.5
EPS Growth (3Y)(%) -6.90
XRAY's EPS Growth (3Y)(%) is ranked lower than
73% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.60 vs. XRAY: -6.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XRAY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.9  Med: 9.60 Max: 88.4
Current: -6.9
-32.9
88.4
» XRAY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

XRAY Guru Trades in Q2 2015

Vanguard Health Care Fund 3,458,900 sh (+6.14%)
Chuck Royce 73,600 sh (unchged)
Jim Simons Sold Out
Mario Gabelli 163,450 sh (-2.89%)
Paul Tudor Jones 8,874 sh (-62.46%)
Joel Greenblatt 253,141 sh (-82.89%)
» More
Q3 2015

XRAY Guru Trades in Q3 2015

George Soros 9,800 sh (New)
Ray Dalio 14,000 sh (New)
Chris Davis 55,500 sh (New)
Andreas Halvorsen 50,000 sh (New)
Vanguard Health Care Fund 4,318,200 sh (+24.84%)
Chuck Royce 73,600 sh (unchged)
Mario Gabelli 147,550 sh (-9.73%)
Joel Greenblatt 194,959 sh (-22.98%)
Paul Tudor Jones 6,371 sh (-28.21%)
» More
Q4 2015

XRAY Guru Trades in Q4 2015

Jim Simons 300,858 sh (New)
Andreas Halvorsen 1,035,264 sh (+1970.53%)
Chris Davis 57,200 sh (+3.06%)
Ray Dalio Sold Out
George Soros Sold Out
Mario Gabelli 146,350 sh (-0.81%)
Vanguard Health Care Fund 3,669,300 sh (-15.03%)
Chuck Royce 58,900 sh (-19.97%)
Paul Tudor Jones 3,900 sh (-38.79%)
Joel Greenblatt 64,978 sh (-66.67%)
» More
Q1 2016

XRAY Guru Trades in Q1 2016

Ruane Cunniff 4,843,324 sh (New)
Columbia Wanger 890,432 sh (New)
Joel Greenblatt 412,656 sh (+535.07%)
Paul Tudor Jones 7,300 sh (+87.18%)
Jim Simons Sold Out
Andreas Halvorsen Sold Out
Chris Davis Sold Out
Chuck Royce 56,000 sh (-4.92%)
Mario Gabelli 130,610 sh (-10.76%)
Vanguard Health Care Fund 1,904,590 sh (-48.09%)
» More
» Details

Insider Trades

Latest Guru Trades with XRAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:OTCPK:CLPBY, OTCPK:TRUMY, OTCPK:OCPNY, NYSE:BCR, NYSE:WAT, NYSE:MTD, NAS:HOLX, NYSE:RMD, NYSE:COO, NAS:ILMN, NAS:SIRO, OTCPK:SAUHY, NYSE:STE, NYSE:WST, OTCPK:GNGBY, NYSE:BAX, NYSE:HRC, NYSE:CMN, OTCPK:ANSLF, OTCPK:AMFPF » details
Traded in other countries:DY2.Germany,
DENTSPLY International Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. The Company also manufactures and markets other consumable medical device products.

Dentsply Sirona Inc, formerly DENTSPLY International Inc was incorporated in 1899 in Delaware. The Company is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. The Company also manufactures and markets other consumable medical device products. The Company's main product categories are dental consumable products, dental laboratory products, dental specialty products and consumable medical device products. The Company conducted its business through four operating segments. All of the Company's segments are mainly engaged in the design, manufacture and distribution of dental and medical products in four principal product categories: dental consumable products; dental laboratory products; dental specialty products; and consumable medical device products. Dental consumable products consist of dental sundries and small equipment used in dental offices for the treatment of patients. The Company's dental sundry products in the dental consumable products category include dental anesthetics, prophylaxis paste, dental sealants, impression materials, restorative materials, tooth whiteners and topical fluoride. Dental laboratory products are used in the preparation of dental appliances by dental laboratories. The Company's products in the dental laboratory products category include dental prosthetics, including artificial teeth, precious metal dental alloys, dental ceramics and crown and bridge materials. Dental specialty products are specialized treatment products used within the dental office and laboratory settings. The Company's products in this category include endodontic (root canal) instruments and materials, implants and related products, bone grafting materials, 3D digital implantology, dental lasers and orthodontic appliances and accessories. Consumable medical device products consist mainly of urological products including catheters, certain surgical products, medical drills and other non-medical products. The Company conducts its business in the United States of America ('U.S.'), as well as in over 120 foreign countries, principally through its foreign subsidiaries. The Company has presence in the European market, particularly in Germany, Sweden, Switzerland, France, Italy and the United Kingdom as well as in Canada. The Company also has market presence in the countries of the Commonwealth of Independent States ('CIS'), Central and South America and the Pacific Rim. The Company's products are subject to regulation by, among other governmental entities, the U.S. Food and Drug Administration.

Ratios

vs
industry
vs
history
P/E(ttm) 31.08
XRAY's P/E(ttm) is ranked lower than
57% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.89 vs. XRAY: 31.08 )
Ranked among companies with meaningful P/E(ttm) only.
XRAY' s P/E(ttm) Range Over the Past 10 Years
Min: 12.19  Med: 21.86 Max: 116
Current: 31.08
12.19
116
Forward P/E 22.99
XRAY's Forward P/E is ranked lower than
54% of the 41 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.32 vs. XRAY: 22.99 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.08
XRAY's PE(NRI) is ranked lower than
57% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.89 vs. XRAY: 31.08 )
Ranked among companies with meaningful PE(NRI) only.
XRAY' s PE(NRI) Range Over the Past 10 Years
Min: 12.2  Med: 21.89 Max: 116
Current: 31.08
12.2
116
Price/Owner Earnings (ttm) 35.61
XRAY's Price/Owner Earnings (ttm) is ranked lower than
62% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.98 vs. XRAY: 35.61 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
XRAY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.21  Med: 20.17 Max: 104.95
Current: 35.61
12.21
104.95
P/B 1.74
XRAY's P/B is ranked higher than
70% of the 207 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. XRAY: 1.74 )
Ranked among companies with meaningful P/B only.
XRAY' s P/B Range Over the Past 10 Years
Min: 1.67  Med: 2.78 Max: 4.65
Current: 1.74
1.67
4.65
P/S 3.37
XRAY's P/S is ranked lower than
55% of the 212 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. XRAY: 3.37 )
Ranked among companies with meaningful P/S only.
XRAY' s P/S Range Over the Past 10 Years
Min: 1.59  Med: 2.41 Max: 3.59
Current: 3.37
1.59
3.59
PFCF 24.66
XRAY's PFCF is ranked higher than
56% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.29 vs. XRAY: 24.66 )
Ranked among companies with meaningful PFCF only.
XRAY' s PFCF Range Over the Past 10 Years
Min: 12.38  Med: 19.71 Max: 28.31
Current: 24.66
12.38
28.31
POCF 20.59
XRAY's POCF is ranked lower than
64% of the 103 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.88 vs. XRAY: 20.59 )
Ranked among companies with meaningful POCF only.
XRAY' s POCF Range Over the Past 10 Years
Min: 10.45  Med: 15.31 Max: 21.94
Current: 20.59
10.45
21.94
EV-to-EBIT 42.50
XRAY's EV-to-EBIT is ranked lower than
81% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.84 vs. XRAY: 42.50 )
Ranked among companies with meaningful EV-to-EBIT only.
XRAY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.7  Med: 18.70 Max: 59.5
Current: 42.5
9.7
59.5
EV-to-EBITDA 30.84
XRAY's EV-to-EBITDA is ranked lower than
81% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.39 vs. XRAY: 30.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
XRAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.4  Med: 14.70 Max: 39.7
Current: 30.84
8.4
39.7
PEG 5.29
XRAY's PEG is ranked lower than
84% of the 61 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. XRAY: 5.29 )
Ranked among companies with meaningful PEG only.
XRAY' s PEG Range Over the Past 10 Years
Min: 0.65  Med: 3.59 Max: 39.63
Current: 5.29
0.65
39.63
Shiller P/E 30.48
XRAY's Shiller P/E is ranked higher than
69% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.46 vs. XRAY: 30.48 )
Ranked among companies with meaningful Shiller P/E only.
XRAY' s Shiller P/E Range Over the Past 10 Years
Min: 18.4  Med: 26.04 Max: 46.19
Current: 30.48
18.4
46.19
Current Ratio 2.11
XRAY's Current Ratio is ranked lower than
62% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. XRAY: 2.11 )
Ranked among companies with meaningful Current Ratio only.
XRAY' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.77 Max: 3.9
Current: 2.11
1.2
3.9
Quick Ratio 1.46
XRAY's Quick Ratio is ranked lower than
59% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. XRAY: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
XRAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 1.07 Max: 2.98
Current: 1.46
0.76
2.98
Days Inventory 120.02
XRAY's Days Inventory is ranked higher than
54% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.38 vs. XRAY: 120.02 )
Ranked among companies with meaningful Days Inventory only.
XRAY' s Days Inventory Range Over the Past 10 Years
Min: 91.22  Med: 101.08 Max: 114.74
Current: 120.02
91.22
114.74
Days Sales Outstanding 81.77
XRAY's Days Sales Outstanding is ranked lower than
76% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.94 vs. XRAY: 81.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
XRAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.12  Med: 56.27 Max: 61.52
Current: 81.77
53.12
61.52
Days Payable 85.44
XRAY's Days Payable is ranked higher than
67% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.12 vs. XRAY: 85.44 )
Ranked among companies with meaningful Days Payable only.
XRAY' s Days Payable Range Over the Past 10 Years
Min: 31.01  Med: 36.57 Max: 43.97
Current: 85.44
31.01
43.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.48
XRAY's Dividend Yield is ranked lower than
86% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. XRAY: 0.48 )
Ranked among companies with meaningful Dividend Yield only.
XRAY' s Dividend Yield Range Over the Past 10 Years
Min: 0.35  Med: 0.53 Max: 0.85
Current: 0.48
0.35
0.85
Dividend Payout 0.14
XRAY's Dividend Payout is ranked higher than
87% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.32 vs. XRAY: 0.14 )
Ranked among companies with meaningful Dividend Payout only.
XRAY' s Dividend Payout Range Over the Past 10 Years
Min: 0.06  Med: 0.11 Max: 5.67
Current: 0.14
0.06
5.67
Dividend Growth (3y) 9.60
XRAY's Dividend Growth (3y) is ranked lower than
59% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.10 vs. XRAY: 9.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
XRAY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 3.2  Med: 9.60 Max: 14.8
Current: 9.6
3.2
14.8
Forward Dividend Yield 0.50
XRAY's Forward Dividend Yield is ranked lower than
88% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. XRAY: 0.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.71
XRAY's Yield on cost (5-Year) is ranked lower than
81% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.61 vs. XRAY: 0.71 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XRAY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.52  Med: 0.79 Max: 1.26
Current: 0.71
0.52
1.26
3-Year Average Share Buyback Ratio 0.50
XRAY's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. XRAY: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XRAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.1  Med: 0.60 Max: 2.2
Current: 0.5
-1.1
2.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.11
XRAY's Price/Projected FCF is ranked higher than
84% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. XRAY: 1.11 )
Ranked among companies with meaningful Price/Projected FCF only.
XRAY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.32 Max: 2.39
Current: 1.11
0.99
2.39
Price/DCF (Earnings Based) 1.90
XRAY's Price/DCF (Earnings Based) is ranked higher than
50% of the 18 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. XRAY: 1.90 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.40
XRAY's Price/Median PS Value is ranked lower than
69% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. XRAY: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
XRAY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.6  Med: 0.94 Max: 1.44
Current: 1.4
0.6
1.44
Price/Peter Lynch Fair Value 5.35
XRAY's Price/Peter Lynch Fair Value is ranked lower than
86% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. XRAY: 5.35 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
XRAY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.7  Med: 1.76 Max: 11.61
Current: 5.35
0.7
11.61
Earnings Yield (Greenblatt) (%) 2.30
XRAY's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. XRAY: 2.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XRAY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.7  Med: 5.30 Max: 10.3
Current: 2.3
1.7
10.3
Forward Rate of Return (Yacktman) (%) 9.56
XRAY's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.73 vs. XRAY: 9.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
XRAY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3.5  Med: 10.40 Max: 31.1
Current: 9.56
-3.5
31.1

More Statistics

Revenue (TTM) (Mil) $2,791
EPS (TTM) $ 2.01
Beta1.29
Short Percentage of Float3.42%
52-Week Range $49.48 - 65.83
Shares Outstanding (Mil)234.23

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 3,854 4,281 4,424
EPS ($) 2.73 3.07 3.25
EPS w/o NRI ($) 2.73 3.07 3.25
EPS Growth Rate
(3Y to 5Y Estimate)
12.01%
Dividends Per Share ($) 0.28 0.30 0.32
» More Articles for NAS:XRAY

Headlines

Articles On GuruFocus.com
Ruane Cunniff Acquires Shares of Dentsply Sirona Jun 23 2016 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
Why I Like These Two Health Care Stocks Aug 29 2014 
Global for Resilience – Columbia Management Selling Update Aug 29 2013 
New Guru Added: Ray Dalio of Bridgewater Associates Dec 02 2011 
DENTSPLY International Inc. Reports Operating Results (10-K) Feb 18 2011 
Align Technologies Takes One in the Teeth Apr 06 2010 
Tom Gayner Top Buys: ITC Holdings Corp., Patterson Companies Inc., Schlumberger Ltd., Walgreen Compa Nov 09 2009 
Richard Aster Jr Buys Zebra Technologies Corp., Bunge Ltd., Liz Claiborne Inc., Sells Time Warner In Nov 03 2006 

More From Other Websites
Dentsply Sirona to Report Second Quarter 2016 Results on August 5 Jul 22 2016
Dentsply Sirona to Report Second Quarter 2016 Results on August 5 Jul 22 2016
DENTSPLY SIRONA, Inc. breached its 50 day moving average in a Bearish Manner : XRAY-US : July 22,... Jul 22 2016
ETF’s with exposure to DENTSPLY SIRONA, Inc. : July 18, 2016 Jul 18 2016
Research Report Initiated on Select Medical Instruments and Supplies Equities Jul 05 2016
What Are Analysts’ Recommendations for Dentsply Sirona? Jul 01 2016
Why Is Dentsply Sirona Acquiring MIS Implants? Jul 01 2016
Dentsply Sirona Inc. -- Moody's: Dentsply Sirona's acquisition of MIS Implants is credit negative;... Jun 28 2016
DENTSPLY Sirona Set to Acquire MIS Implants for $375M Jun 28 2016
DENTSPLY SIRONA INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 27 2016
DENTSPLY Slides on Acquisition News Jun 27 2016
DENTSPLY SIRONA, Inc. breached its 50 day moving average in a Bearish Manner : XRAY-US : June 27,... Jun 27 2016
[$$] Dentsply Sirona to Buy MIS Implants Jun 27 2016
DENTSPLY SIRONA Buys MIS Implants For $375 Million Cash Jun 27 2016
Dentsply Sirona Announces Acquisition of MIS Implants Jun 27 2016
Dentsply Sirona Announces Acquisition of MIS Implants Jun 27 2016
Ruane Cunniff Acquires Shares of Dentsply Sirona Jun 23 2016
DENTSPLY Sirona (XRAY): Q1 Strong, Expansion on Track Jun 20 2016
Quant Funds Express Interest in These Stocks Jun 14 2016
Coverage initiated on Dentsply Sirona by Piper Jaffray Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)